Evidence map›Paper›PMID 39300963›Full record

Trial reportDiabetes, obesity & metabolism2024

Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.

Sarah A MacLeish, Korey K Hood, William H Polonsky, Jamie R Wood, Bruce W Bode, Gregory P Forlenza, Lori M Laffel, Bruce A Buckingham, Amy B Criego, Melissa J Schoelwer and 8 more

Abstract readMulticenter StudyClinical Trial
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Diabetes Technology in the School Setting for Preschool-Aged Children.Journal of diabetes science and technology · 2026
    Article
  3. Transitioning to Omnipod 5Biomedicines · 2026
    Article
  4. A Review of Real-World Evidence About the Use of Automated Insulin Delivery Systems in People With Type 1 Diabetes.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
    Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sarah A MacLeishUniversity Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.
Korey K HoodDepartment of Pediatrics, Psychiatry, & Behavioral Sciences, Stanford University School of Medicine, Stanford Diabetes Research Center, Stanford, California, USA.ORCID 0000-0001-5730-7749
William H PolonskyBehavioral Diabetes Institute, San Diego, California, USA.
Jamie R WoodUniversity Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.
Bruce W BodeAtlanta Diabetes Associates, Atlanta, Georgia, USA.
Gregory P ForlenzaBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Lori M LaffelJoslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
Bruce A BuckinghamDivision of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California, USA.
Amy B CriegoInternational Diabetes Center/HealthPartners Institute, Park Nicollet Clinic Pediatric Endocrinology, Minneapolis, Minnesota, USA.
Melissa J SchoelwerCenter for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA.
Daniel J DeSalvoDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Jennifer L SherrDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
David W HansenDepartment of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA.
Lindsey R ConroyInsulet Corporation, Acton, Massachusetts, USA.
Lauren M HuyettInsulet Corporation, Acton, Massachusetts, USA.
Todd E VienneauInsulet Corporation, Acton, Massachusetts, USA.
Trang T LyInsulet Corporation, Acton, Massachusetts, USA.ORCID 0000-0002-5995-1447
Omnipod 5 in Preschoolers Study Group

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
Insulet CorporationNIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

aimAutomated insulin delivery (AID) systems have demonstrated improved glycaemic outcomes in people with type 1 diabetes (T1D), yet limited data exist on these systems in very young children and their impact on caregivers. We evaluated psychosocial outcomes following use of the tubeless Omnipod® 5 AID System in caregivers of very young children. MATERIALS AND

methodsThis 3-month single-arm, multicentre, pivotal clinical trial enrolled 80 children aged 2.0-5.9 years with T1D to use the Omnipod 5 AID System. Caregivers completed questionnaires assessing psychosocial outcomes-diabetes distress (Problem Areas in Diabetes), hypoglycaemia confidence (Hypoglycemia Confidence Scale), well-being (World Health Organization 5 Well-Being Index), sleep quality (Pittsburgh Sleep Quality Index), insulin delivery satisfaction (Insulin Delivery Satisfaction Survey) and system usability (System Usability Scale) at baseline with standard therapy and after 3 months of AID use.

resultsFollowing 3 months of Omnipod 5 use, caregivers experienced significant improvements across all measures, including diabetes-related psychosocial outcomes (Problem Areas in Diabetes; p < 0.0001, Hypoglycemia Confidence Scale; p < 0.01), well-being (World Health Organization 5 Well-Being Index; p < 0.0001) and perceived system usability (System Usability Scale; p < 0.0001). Significant improvements were seen in the Pittsburgh Sleep Quality Index total score and the overall sleep quality, sleep duration and efficiency subscales (all p < 0.05). Insulin Delivery Satisfaction Survey scores improved on all subscales (greater satisfaction, reduced burden and reduced inconvenience; all p < 0.0001).

conclusionsCaregivers face unique challenges when managing T1D in very young children. While glycaemic metrics have unquestioned importance, these results evaluating psychosocial outcomes reveal additional meaningful benefits and suggest that the Omnipod 5 AID System alleviates some of the burdens caregivers face with diabetes management.

Indexed as

CaregiversDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulinInsulin Infusion SystemsAdultChild, PreschoolFemaleHumansHypoglycemiaMaleSleep QualitySurveys and QuestionnairesHypoglycemic AgentsInsulinclinical trialinsulin pump therapyinsulin therapypatient‐reported outcomes

Identifiers

PMID39300963
PMCPMC11949198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.